Titan Reports Patient Enrollment in Phase III Study of Probuphine® is Ahead of Schedule August 3, 2010
Titan Announces Completion of Re-Registration of the Company With the Securities and Exchange Commission April 27, 2010
Titan Initiates Confirmatory Phase 3 Study of Probuphine(R) in the Treatment of Opioid Addiction March 30, 2010
